Covering: 2000 to August 2025The search for new antimicrobial natural products from microorganisms has been limited by the transcriptional silencing of biosynthetic genes when microbes are cultivated outside their ecological environments. Nevertheless, applying knowledge of the ecological roles, for example, microbial defense against plant pathogens, can improve drug discovery efforts. Interactions between plants and their microbiota, during adaptation to pathogen stress, provide ecological cues that induce microenvironments suppressive to pathogens. This article highlights research linking pathogen-induced plant stress signals to the activation of microbial natural product biosynthesis, emphasizing the need for further studies on how plant metabolites can influence biosynthesis in plant-associated microbes.
{"title":"Microbial natural products activated by plant stress.","authors":"Barbara I Adaikpoh","doi":"10.1039/d5np00062a","DOIUrl":"https://doi.org/10.1039/d5np00062a","url":null,"abstract":"<p><p>Covering: 2000 to August 2025The search for new antimicrobial natural products from microorganisms has been limited by the transcriptional silencing of biosynthetic genes when microbes are cultivated outside their ecological environments. Nevertheless, applying knowledge of the ecological roles, for example, microbial defense against plant pathogens, can improve drug discovery efforts. Interactions between plants and their microbiota, during adaptation to pathogen stress, provide ecological cues that induce microenvironments suppressive to pathogens. This article highlights research linking pathogen-induced plant stress signals to the activation of microbial natural product biosynthesis, emphasizing the need for further studies on how plant metabolites can influence biosynthesis in plant-associated microbes.</p>","PeriodicalId":94,"journal":{"name":"Natural Product Reports","volume":" ","pages":""},"PeriodicalIF":10.6,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146103122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Covering: up to 2026The Stachybotrys fungi have proven to be rich sources of triprenyl meroterpenoids. In addition to natural products typified by the relatively well known K76, stachybotrin, kampanol and stachyflin are the bisabosquals. The first four bisabosquals were discovered in 2001 and found to have a unique molecular structure displaying an all cis benzopyran-fused benzofuran core. Over the past two decades, this family has been extended, while their novel structure has stimulated efforts focused on their chemical synthesis. Herein, we provide a highlight, covering the isolation, biosynthesis and bioactivities of the bisabosquals and seco-bisabosquals along with studies focused on their total syntheses.
{"title":"Isolation and synthesis of bisabosquals, fungal triprenyl phenol meroterpenoids with a densely functionalised bisabolane core.","authors":"James P Shephard, David W Lupton","doi":"10.1039/d5np00085h","DOIUrl":"https://doi.org/10.1039/d5np00085h","url":null,"abstract":"<p><p>Covering: up to 2026The <i>Stachybotrys</i> fungi have proven to be rich sources of triprenyl meroterpenoids. In addition to natural products typified by the relatively well known K76, stachybotrin, kampanol and stachyflin are the bisabosquals. The first four bisabosquals were discovered in 2001 and found to have a unique molecular structure displaying an all <i>cis</i> benzopyran-fused benzofuran core. Over the past two decades, this family has been extended, while their novel structure has stimulated efforts focused on their chemical synthesis. Herein, we provide a highlight, covering the isolation, biosynthesis and bioactivities of the bisabosquals and <i>seco</i>-bisabosquals along with studies focused on their total syntheses.</p>","PeriodicalId":94,"journal":{"name":"Natural Product Reports","volume":" ","pages":""},"PeriodicalIF":10.6,"publicationDate":"2026-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146103078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Covering: 2006-2025Corynanthe alkaloids constitute the largest class of monoterpene indole alkaloids and feature a secologanin-derived carbon skeleton fused to an indole or indole-derived heterocycle. To date, thousands of structurally diverse members have been identified, exhibiting activities ranging from anti-inflammatory and antihypertensive to neuroprotective effects. Growing insight into ajmaline biosynthesis and recent advances in the synthetic construction of corynantheine-type scaffolds have renewed interest in this family. However, contemporary reviews largely emphasize structural diversity and biological function, while offering limited systematic coverage of biosynthetic logic or total-synthesis strategies. The present review compiles corynanthe alkaloids reported between 2006 and 2025 and summarizes their natural sources. It also provides an integrated overview of recent progress in both biosynthetic elucidation and chemical synthesis of simple corynanthe alkaloids and yohimbine alkaloids, alongside a concise survey of their biological activities. Collectively, this review aims to stimulate new perspectives on the discovery and synthetic innovation of corynanthe alkaloids, providing a valuable resource for researchers in natural-product chemistry and drug development.
{"title":"Structure, bioactivity, biosynthesis, and synthesis of corynanthe alkaloids.","authors":"Chenxu Liu, Mengqi Tong, Kouharu Otsuki, Wei Li, Feng Feng, Jie Zhang","doi":"10.1039/d5np00051c","DOIUrl":"https://doi.org/10.1039/d5np00051c","url":null,"abstract":"<p><p>Covering: 2006-2025Corynanthe alkaloids constitute the largest class of monoterpene indole alkaloids and feature a secologanin-derived carbon skeleton fused to an indole or indole-derived heterocycle. To date, thousands of structurally diverse members have been identified, exhibiting activities ranging from anti-inflammatory and antihypertensive to neuroprotective effects. Growing insight into ajmaline biosynthesis and recent advances in the synthetic construction of corynantheine-type scaffolds have renewed interest in this family. However, contemporary reviews largely emphasize structural diversity and biological function, while offering limited systematic coverage of biosynthetic logic or total-synthesis strategies. The present review compiles corynanthe alkaloids reported between 2006 and 2025 and summarizes their natural sources. It also provides an integrated overview of recent progress in both biosynthetic elucidation and chemical synthesis of simple corynanthe alkaloids and yohimbine alkaloids, alongside a concise survey of their biological activities. Collectively, this review aims to stimulate new perspectives on the discovery and synthetic innovation of corynanthe alkaloids, providing a valuable resource for researchers in natural-product chemistry and drug development.</p>","PeriodicalId":94,"journal":{"name":"Natural Product Reports","volume":" ","pages":""},"PeriodicalIF":10.6,"publicationDate":"2026-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146049585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Covering: 2005 to July 2025Methicillin-resistant Staphylococcus aureus (MRSA), emerging as one of the most common multidrug-resistant (MDR) bacterial strains, has posed a serious threat to global healthcare over the past few decades due to its high rates of morbidity and mortality. Aromatic polyketides, renowned for their intricate structures and diverse biological activities, are a remarkable bioresource for developing new antimicrobial agents. This review systematically classifies all natural aromatic polyketides (from 2005 to 2025) with anti-MRSA activity (MICs < 10 µg mL-1) from microbial sources, and summarizes their structure-activity relationships, additional bioactivities, and reported antibacterial mechanisms. Meanwhile, the clinical utilization status, limitations, and ongoing challenges associated with existing anti-MRSA aromatic polyketide antibiotics were assessed, alongside valuable perspectives on the potential advancement of aromatic polyketide derivatives. Additionally, the review provides further insights into drug innovation and future trends in medicinal research regarding the rational development of anti-MRSA aromatic polyketide drugs, offering a valuable reference for future research and pharmaceutical development.
{"title":"Microbe-derived aromatic polyketides toward MRSA infection: current advances and perspectives.","authors":"Fangfang Duan, Jiaying Lai, Linjie Wei, Siran Li, Polina Lopukhina, Zihuan Sang, Chen Chen, Xiaoyi Wei, Hongxin Liu, Haibo Tan","doi":"10.1039/d5np00061k","DOIUrl":"https://doi.org/10.1039/d5np00061k","url":null,"abstract":"<p><p>Covering: 2005 to July 2025Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA), emerging as one of the most common multidrug-resistant (MDR) bacterial strains, has posed a serious threat to global healthcare over the past few decades due to its high rates of morbidity and mortality. Aromatic polyketides, renowned for their intricate structures and diverse biological activities, are a remarkable bioresource for developing new antimicrobial agents. This review systematically classifies all natural aromatic polyketides (from 2005 to 2025) with anti-MRSA activity (MICs < 10 µg mL<sup>-1</sup>) from microbial sources, and summarizes their structure-activity relationships, additional bioactivities, and reported antibacterial mechanisms. Meanwhile, the clinical utilization status, limitations, and ongoing challenges associated with existing anti-MRSA aromatic polyketide antibiotics were assessed, alongside valuable perspectives on the potential advancement of aromatic polyketide derivatives. Additionally, the review provides further insights into drug innovation and future trends in medicinal research regarding the rational development of anti-MRSA aromatic polyketide drugs, offering a valuable reference for future research and pharmaceutical development.</p>","PeriodicalId":94,"journal":{"name":"Natural Product Reports","volume":" ","pages":""},"PeriodicalIF":10.6,"publicationDate":"2026-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146027704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Abdul Bari Shah, Young Jun Kim, Kyeong Seon Lee, Sang Hoon Han, Youngjoo Byun, Ki Yong Lee
Covering: upto 2025The increasing prevalence of allergic diseases and immunological disorders is a significant public health issue requiring the development of novel therapeutic approaches. Interleukins are prime therapeutic targets because they are crucial for immune control and allergic aetiology. Naturally occurring bioactive compounds show tremendous promise for altering interleukin signalling, providing therapeutic advantages with potentially fewer adverse effects than those of synthesised drugs. This review highlights key bioactive substances that influence interleukin pathways, including flavonoids, polyphenols, terpenoids, alkaloids, and plant extracts. These compounds exhibit multiple mechanisms of action, including enhanced anti-inflammatory responses and reduced production of pro-inflammatory cytokines. Controlling several interleukin-mediated pathways, including IL-6 and IL-17, IL-1β and IL-10, as well as IL-4 and IL-13, has shown promise, thus showing substantial anti-allergic properties. These compounds exert modulatory effects by reducing Th2-mediated allergic reactions. This review examined their binding affinities to important interleukins to support the therapeutic potential of these bioactive metabolites. Although the results are encouraging, some issues remain, including variations in compound bioavailability, formulation issues, and insufficient clinical validation. This review addresses these challenges and highlights the potential use of bioactive compounds in innovative approaches aimed at interleukin-mediated pathways in immunological control and allergies.
{"title":"Natural products modulating interleukin-mediated pathways for anti-allergic and immunomodulatory effects.","authors":"Abdul Bari Shah, Young Jun Kim, Kyeong Seon Lee, Sang Hoon Han, Youngjoo Byun, Ki Yong Lee","doi":"10.1039/d5np00074b","DOIUrl":"https://doi.org/10.1039/d5np00074b","url":null,"abstract":"<p><p>Covering: upto 2025The increasing prevalence of allergic diseases and immunological disorders is a significant public health issue requiring the development of novel therapeutic approaches. Interleukins are prime therapeutic targets because they are crucial for immune control and allergic aetiology. Naturally occurring bioactive compounds show tremendous promise for altering interleukin signalling, providing therapeutic advantages with potentially fewer adverse effects than those of synthesised drugs. This review highlights key bioactive substances that influence interleukin pathways, including flavonoids, polyphenols, terpenoids, alkaloids, and plant extracts. These compounds exhibit multiple mechanisms of action, including enhanced anti-inflammatory responses and reduced production of pro-inflammatory cytokines. Controlling several interleukin-mediated pathways, including IL-6 and IL-17, IL-1β and IL-10, as well as IL-4 and IL-13, has shown promise, thus showing substantial anti-allergic properties. These compounds exert modulatory effects by reducing Th2-mediated allergic reactions. This review examined their binding affinities to important interleukins to support the therapeutic potential of these bioactive metabolites. Although the results are encouraging, some issues remain, including variations in compound bioavailability, formulation issues, and insufficient clinical validation. This review addresses these challenges and highlights the potential use of bioactive compounds in innovative approaches aimed at interleukin-mediated pathways in immunological control and allergies.</p>","PeriodicalId":94,"journal":{"name":"Natural Product Reports","volume":" ","pages":""},"PeriodicalIF":10.6,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146016675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hidayat Hussain, Satyajit D Sarker, Lutfun Nahar, Ishtiaq Ahmed
Covering: up to December 2024Trimers constitute a group of natural products with considerable structural variability, formed through homo- or hetero-trimeric coupling of three monomeric units. They usually have complex structures because they are made up of different monomeric natural products as structural units, and undergo trimerization. These secondary metabolites have captured the interest of synthetic chemists and biological scientists due to their rarity and significant biological activities. In this review, we highlight some interesting trimeric natural products, showcasing the diversity of their structures, biosynthesis, and biomimetic synthesis, as well as their biological functions. These pathways could inspire the discovery and synthesis of more trimer secondary metabolites and further biological investigations.
{"title":"Trimeric natural products: structural diversity, biosynthesis, bioactivities and chemical synthesis.","authors":"Hidayat Hussain, Satyajit D Sarker, Lutfun Nahar, Ishtiaq Ahmed","doi":"10.1039/d5np00065c","DOIUrl":"https://doi.org/10.1039/d5np00065c","url":null,"abstract":"<p><p>Covering: up to December 2024Trimers constitute a group of natural products with considerable structural variability, formed through homo- or hetero-trimeric coupling of three monomeric units. They usually have complex structures because they are made up of different monomeric natural products as structural units, and undergo trimerization. These secondary metabolites have captured the interest of synthetic chemists and biological scientists due to their rarity and significant biological activities. In this review, we highlight some interesting trimeric natural products, showcasing the diversity of their structures, biosynthesis, and biomimetic synthesis, as well as their biological functions. These pathways could inspire the discovery and synthesis of more trimer secondary metabolites and further biological investigations.</p>","PeriodicalId":94,"journal":{"name":"Natural Product Reports","volume":" ","pages":""},"PeriodicalIF":10.6,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146016680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anthony R. Carroll , Brent R. Copp , Tanja Grkovic , Robert A. Keyzers , Michèle R. Prinsep
Covering: January to the end of December 2024
This review covers the literature published in 2024 for marine natural products (MNPs), with 617 citations (578 for the period January to December 2024) referring to compounds isolated from marine microorganisms and phytoplankton, green, brown and red algae, sponges, cnidarians, bryozoans, molluscs, tunicates, echinoderms, the submerged parts of mangroves and other intertidal plants. The emphasis is on new compounds (1256 in 336 papers for 2024), together with the relevant biological activities, source organisms and country of origin. Pertinent reviews, biosynthetic studies, first syntheses, and syntheses that led to the revision of structures or stereochemistries, have been included. An analysis of the role of artificial intelligence in marine natural products research is discussed.
{"title":"Marine natural products","authors":"Anthony R. Carroll , Brent R. Copp , Tanja Grkovic , Robert A. Keyzers , Michèle R. Prinsep","doi":"10.1039/d5np00080g","DOIUrl":"10.1039/d5np00080g","url":null,"abstract":"<div><div>Covering: January to the end of December 2024</div></div><div><div>This review covers the literature published in 2024 for marine natural products (MNPs), with 617 citations (578 for the period January to December 2024) referring to compounds isolated from marine microorganisms and phytoplankton, green, brown and red algae, sponges, cnidarians, bryozoans, molluscs, tunicates, echinoderms, the submerged parts of mangroves and other intertidal plants. The emphasis is on new compounds (1256 in 336 papers for 2024), together with the relevant biological activities, source organisms and country of origin. Pertinent reviews, biosynthetic studies, first syntheses, and syntheses that led to the revision of structures or stereochemistries, have been included. An analysis of the role of artificial intelligence in marine natural products research is discussed.</div></div>","PeriodicalId":94,"journal":{"name":"Natural Product Reports","volume":"43 1","pages":"Pages 89-131"},"PeriodicalIF":10.6,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146002637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Natural products (NPs) have long been foundational in medicine, from ancient herbal remedies to the discovery of transformative drugs like morphine and quinine. The mid-20th century marked a ‘golden age’ for antibiotic discovery from natural sources, which then expanded into other therapeutic areas. However, by the late 20th century, other technological advances had shifted NPs from being a central component of the discovery process to one of several options. This review explores the current role of NPs in pharmaceuticals by analysing NP-derived (NP-D) drugs approved since 2014 and clinical candidates in development as of the end of 2024. 58 NP-related drugs launched between January 2014 and June 2025 were identified, which included 45 NP and NP-D new chemical entities (NCEs) and 13 NP-antibody drug conjugates (NP-ADCs). Next, all 579 drugs—388 (67%) of which were NCEs and 191 (33%) were new biological entities (NBEs)—approved globally from 2014 to 2024 were analysed. In total, 56 (9.7%) of these 579 drugs were classified as NPs or NP-Ds using this review's NP definition: 44 NCEs (7.6% overall; 11.3% of NCEs) and 12 NP-ADCs (2.1% overall; 6.3% of NBEs). The number of new NP-D NCEs and NP-ADCs has fluctuated between 0 and 8 annually since 2014, with an average of five approvals per year. Next, 125 NP and NP-D compounds were identified that were undergoing clinical trials or in the registration phase at the end of December 2024. Thirty-three new pharmacophores not previously found in approved drugs are now in development; however, only one has been discovered in the past 15 years. This review highlights the enduring promise of NPs, despite their diminished role in drug discovery, and advocates for renewed emphasis on bioassay-guided isolation and mode of action studies to identify new drug leads.
{"title":"Natural product-derived compounds in clinical trials and drug approvals","authors":"Mark S. Butler , Robert J. Capon , Mark A. T. Blaskovich , Ian R. Henderson","doi":"10.1039/d5np00031a","DOIUrl":"10.1039/d5np00031a","url":null,"abstract":"<div><div>Covering: January 2014–June 2025. Previous review: <em>Natural Product Reports</em>, 2014, <strong>31</strong>, 1612</div></div><div><div>Natural products (NPs) have long been foundational in medicine, from ancient herbal remedies to the discovery of transformative drugs like morphine and quinine. The mid-20th century marked a ‘golden age’ for antibiotic discovery from natural sources, which then expanded into other therapeutic areas. However, by the late 20th century, other technological advances had shifted NPs from being a central component of the discovery process to one of several options. This review explores the current role of NPs in pharmaceuticals by analysing NP-derived (NP-D) drugs approved since 2014 and clinical candidates in development as of the end of 2024. 58 NP-related drugs launched between January 2014 and June 2025 were identified, which included 45 NP and NP-D new chemical entities (NCEs) and 13 NP-antibody drug conjugates (NP-ADCs). Next, all 579 drugs—388 (67%) of which were NCEs and 191 (33%) were new biological entities (NBEs)—approved globally from 2014 to 2024 were analysed. In total, 56 (9.7%) of these 579 drugs were classified as NPs or NP-Ds using this review's NP definition: 44 NCEs (7.6% overall; 11.3% of NCEs) and 12 NP-ADCs (2.1% overall; 6.3% of NBEs). The number of new NP-D NCEs and NP-ADCs has fluctuated between 0 and 8 annually since 2014, with an average of five approvals per year. Next, 125 NP and NP-D compounds were identified that were undergoing clinical trials or in the registration phase at the end of December 2024. Thirty-three new pharmacophores not previously found in approved drugs are now in development; however, only one has been discovered in the past 15 years. This review highlights the enduring promise of NPs, despite their diminished role in drug discovery, and advocates for renewed emphasis on bioassay-guided isolation and mode of action studies to identify new drug leads.</div></div>","PeriodicalId":94,"journal":{"name":"Natural Product Reports","volume":"43 1","pages":"Pages 20-88"},"PeriodicalIF":10.6,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145022490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Terpenoids constitute nature's largest and most structurally diverse class of natural products, with extensive applications in medicine, agriculture, and fragrance industries. Class I terpene synthases (TSs) create this remarkable diversity by converting linear isoprenoid diphosphates into complex, often polycyclic frameworks through intricate carbocation cascades. This review examines strategies for engineering TSs to generate diverse terpene skeletons—a key objective in synthetic biology. We summarize four core approaches: structure-guided design targeting active sites, water networks, and conserved motifs; evolutionary methods leveraging natural variation and phylogenetic insights; mechanism-focused engineering controlling specific carbocation intermediates; and techniques extending beyond the active site through second-shell modifications and contact mapping. These approaches are complemented by semi-rational and random methods including alanine scanning, saturation mutagenesis, and directed evolution, often enhanced by computational modeling and high-throughput screening. While the complexity of TS catalysis and often weak sequence-function correlations create significant engineering challenges, integration of structural biology, computational simulations, diverse engineering techniques, and advanced screening methods is steadily improving outcomes. Future advances in machine learning, mechanistic understanding, screening technologies, and metabolic engineering integration will further expand access to novel terpenoid chemical space for biotechnological exploration.
{"title":"Engineering class I terpene synthases for skeletal diversity: strategies and applications","authors":"Xingming Pan , Haixin Li , Liao-Bin Dong","doi":"10.1039/d5np00066a","DOIUrl":"10.1039/d5np00066a","url":null,"abstract":"<div><div>Covering: up to August 2025</div></div><div><div>Terpenoids constitute nature's largest and most structurally diverse class of natural products, with extensive applications in medicine, agriculture, and fragrance industries. Class I terpene synthases (TSs) create this remarkable diversity by converting linear isoprenoid diphosphates into complex, often polycyclic frameworks through intricate carbocation cascades. This review examines strategies for engineering TSs to generate diverse terpene skeletons—a key objective in synthetic biology. We summarize four core approaches: structure-guided design targeting active sites, water networks, and conserved motifs; evolutionary methods leveraging natural variation and phylogenetic insights; mechanism-focused engineering controlling specific carbocation intermediates; and techniques extending beyond the active site through second-shell modifications and contact mapping. These approaches are complemented by semi-rational and random methods including alanine scanning, saturation mutagenesis, and directed evolution, often enhanced by computational modeling and high-throughput screening. While the complexity of TS catalysis and often weak sequence-function correlations create significant engineering challenges, integration of structural biology, computational simulations, diverse engineering techniques, and advanced screening methods is steadily improving outcomes. Future advances in machine learning, mechanistic understanding, screening technologies, and metabolic engineering integration will further expand access to novel terpenoid chemical space for biotechnological exploration.</div></div>","PeriodicalId":94,"journal":{"name":"Natural Product Reports","volume":"43 1","pages":"Pages 227-270"},"PeriodicalIF":10.6,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145712616","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Hidayat Hussain , K. N. Houk , Ching Ching Lam , Satyajit D. Sarker , Lutfun Nahar
Covering: up to June 2025
High selectivity is generally observed in the biosynthesis of complex natural molecules. Evolution usually leads to enzymes that favor the formation of a particular isomer rather than one of the many other potential molecules. Recent discoveries of enzymes with multiple sequential post-transition state bifurcations (PTSB) after ambimodal transition states demonstrate the impact of dynamics on selectivity. PTSB cause a single ambimodal transition state (TS) to form multiple products. This is different from conventional energetically-controlled mechanisms, where two discrete transition states have different energy barriers. Selectivity arising from ambimodal TSs cannot be fully explained by transition state theory. The presence of PTSB on enzyme catalyzed reaction surfaces has been discovered recently at a significantly higher rate. For both uncatalyzed and catalyzed reactions, computational chemists are devising techniques to comprehend which elements of molecular structure and vibrations govern the product selectivity in systems that contain bifurcations. This review describes enzyme-catalyzed reactions involving ambimodal transition states, and recent advances in understanding how enzymes control selectivity in such reactions.
{"title":"Progress, challenges, and opportunities in the field of biosynthetic reactions involving ambimodal transition states","authors":"Hidayat Hussain , K. N. Houk , Ching Ching Lam , Satyajit D. Sarker , Lutfun Nahar","doi":"10.1039/d5np00064e","DOIUrl":"10.1039/d5np00064e","url":null,"abstract":"<div><div>Covering: up to June 2025</div></div><div><div>High selectivity is generally observed in the biosynthesis of complex natural molecules. Evolution usually leads to enzymes that favor the formation of a particular isomer rather than one of the many other potential molecules. Recent discoveries of enzymes with multiple sequential post-transition state bifurcations (PTSB) after ambimodal transition states demonstrate the impact of dynamics on selectivity. PTSB cause a single ambimodal transition state (TS) to form multiple products. This is different from conventional energetically-controlled mechanisms, where two discrete transition states have different energy barriers. Selectivity arising from ambimodal TSs cannot be fully explained by transition state theory. The presence of PTSB on enzyme catalyzed reaction surfaces has been discovered recently at a significantly higher rate. For both uncatalyzed and catalyzed reactions, computational chemists are devising techniques to comprehend which elements of molecular structure and vibrations govern the product selectivity in systems that contain bifurcations. This review describes enzyme-catalyzed reactions involving ambimodal transition states, and recent advances in understanding how enzymes control selectivity in such reactions.</div></div>","PeriodicalId":94,"journal":{"name":"Natural Product Reports","volume":"43 1","pages":"Pages 7-19"},"PeriodicalIF":10.6,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145538118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}